Read twice and referred to the Committee on Commerce, Science, and Transportation.
The bill regulates pharmacy benefit managers (PBMs) by prohibiting certain deceptive pricing and clawback practices, requiring extensive annual disclosures to the Federal Trade Commission (FTC) and HHS, and forbidding knowingly false reporting to federal agencies. It mandates whistleblower protections, authorizes FTC enforcement with civil penalties (up to $1,000,000 per violation), directs FTC and GAO studies and reports to Congress, and preserves state law and patient privacy protections.
Left emphasizes transparency and pharmacy protections; right emphasizes regulatory burden and federal overreach.
Relatively narrow, constituent-facing drug-price reform could attract bipartisan support but faces industry pushback and lobbying.
The bill regulates pharmacy benefit managers (PBMs) by prohibiting certain deceptive pricing and clawback practices, requiring extensive annual disclosures to the Federal Trade Commission (FTC) and HHS, and forbidding knowingly false reporting to federal agencies.
It mandates whistleblower protections, authorizes FTC enforcement with civil penalties (up to $1,000,000 per violation), directs FTC and GAO studies and reports to Congress, and preserves state law and patient privacy protections.
Content is targeted and actionable, but strong vested-industry opposition and substantive regulatory expansion reduce chances absent compromise.
How solid the drafting looks.
Left emphasizes transparency and pharmacy protections; right emphasizes regulatory burden and federal overreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Left emphasizes transparency and pharmacy protections; right emphasizes regulatory burden and federal overreach.
Likely generally supportive: the bill targets PBM opacity, clawbacks, and rebate retention while increasing transparency and protecting whistleblowers.
Supporters would view it as a tool to reduce intermediary rent-seeking and protect independent pharmacies and patients, though effects on retail drug prices are somewhat uncertain.
Pragmatic but cautious: the bill's transparency and anti-deception provisions are constructive, but mandated reporting, FTC enforcement, and penalties create compliance costs and legal exposure.
The centrist view weighs improved data and consumer protections against administrative burden and unintended market consequences.
Skeptical: views this as expanded federal regulation of private contracts and markets, increasing FTC authority and costly reporting.
While fraud prevention and pharmacy protection are acceptable goals, the conservative view worries about overreach, litigation exposure, and adverse market distortions.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is targeted and actionable, but strong vested-industry opposition and substantive regulatory expansion reduce chances absent compromise.
The bill has not accumulated any surfaced votes yet.
Left emphasizes transparency and pharmacy protections; right emphasizes regulatory burden and federal overreach.
Content is targeted and actionable, but strong vested-industry opposition and substantive regulatory expansion reduce chances absent compro…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Pharmacy Benefit Manager Transparency Act of 2025.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.